聯系方式

辦公電話：020-39943044

電子郵箱：zhangxlei5@mail.sysu.edu.cn

辦公地址：廣州市大學城外環東路132号 太阳集团1088vip，郵編：510006

 

簡單介紹

張小雷，中山大學“百人計劃二期”引進人才，教授/博士生導師。主要從事腫瘤靶向治療及藥理毒理學研究。目前主持國家自然科學基金、廣東省自然科學基金、廣州市科技創新計劃等多項科研項目。近5年來，以通訊作者在Cancer Research, JHO, Redox Biology, APSB, Theranostics, BJP,JMC等權威期刊發表論文20多篇， 國際PCT專利7項，獲得發明專利授權22項。聚焦“難成藥靶點”，作為主要貢獻者發現了一系列轉錄因子STAT3抑制劑、G蛋白抑制劑、Kras抑制劑、腺苷受體A2AR靶向藥物，及寡核苷酸藥物分子。如WZ-2-033, BP-1-102, GQ127等，其中BP-1-102于2017年以1900萬美元實現轉讓，目前進入臨床I期研究，腫瘤免疫調節劑DX82正在推進臨床試驗許可及中美雙報。

 

研究興趣

1）抗腫瘤、抗衰老、眼科疾病創新藥物發現與成藥性研究 (Drug hunting for cancer、 aging and eye related diseases)

2）腫瘤微環境、治療抵抗與幹預新策略 (Tumor microenvironment and metabolism in drug resistance)

---歡迎有興趣的同學報考，歡迎博士後加入，創新藥創未來！

 

教育經曆

吉林大學生命科學學院，本科 (BS)

吉林大學生命科學學院，碩士 (MS)

中佛羅裡達大學醫學院，博士 (PhD)

 

工作經曆

2017.09-至今 太阳集团1088vip，副教授、教授、博士生導師

2018-2024 中山大學實驗動物中心，副主任

2014-2017 美國佛羅裡達醫院轉化醫學研究所，研究科學家

2011-2014 美國Moffitt癌症中心，博士後、I級研究科學家

 

本科及研究生教學

本科課程：《人體解剖生理學》 、《人體解剖生理學實驗》、《病理生理學》、《藥理學》、《藥理學實驗》、《藥理學案例分析》、《動物實驗技術》、《實驗動物學》

研究生課程：《細胞信号轉導的分子基礎與功能調控》、《藥理學研究進展》、《藥物篩選技術與進展》、《藥物現代評價實驗方法》、《醫學實驗動物學與技術》

 

社會/學術任職

中國藥理學會表觀遺傳學專業委員會，委員

廣東省藥理學會藥物毒理專業委員會，常務委員

廣東省藥理學會藥物篩選與評價專業委員會，常務委員

中山大學實驗動物管理與使用委員會（IACUC），委員

廣東省藥理學會抗炎免疫藥理專業委員會，委員

廣東省抗癌協會抗腫瘤藥物專業委員會，委員

廣東省藥理學會腫瘤藥理專業委員會，委員

廣東省廣東省抗癌協會腫瘤代謝專業委員會，委員

中西醫結合學會實驗醫學專業委員會，常務委員

廣東省精準醫學應用學會疾病模型分會，委員

 

科研項目

  1. 國家自然科學基金面上項目，2023年1月-2026年12月，項目負責人
  2. 國家自然科學基金面上項目，2020年1月-2023年12月，項目負責人
  3. 廣東自然科學基金面上項目，2024年1月-2026年12月，項目負責人
  4. 廣東自然科學基金面上項目，2022年1月-2024年12月，項目負責人
  5. 廣東自然科學基金面上項目，2019年10月-2022年9月，項目負責人
  6. 粵港澳聯合創新項目：改善腫瘤免疫治療敏感性創新藥物的發現及臨床前研究，2022年1月-2024年12月，中大方負責人
  7. 廣州市基礎與應用基礎研究項目，2020年4月-2023年3月，項目負責人
  8. 中央高校基本科研業務費專項資金資助-中山大學青年教師培育項目，2019年1月-2022年12月，項目負責人
  9. 中山大學“百人計劃二期”啟動項目，2017年9月-2022年9月，項目負責人
  10. 橫向項目：為臨床試驗藥物提供藥理學證據支撐  HT-99982022-020n，HT-99982023-029n，HT-99982023-029n，項目負責人
  11. 廣東省重點領域研發計劃-嶺南中草藥活性化合物庫的構建及重大疾病候選藥物發現，800萬，2020年1月-2023年12月，參與人
  12. 廣州市科技創新計劃重點項目，基于胃癌分子可視化示蹤的精準外科新技術及多組合融合的創新綜合治療研究，500萬， 2022.01-2025.12，參與人
  13. 廣州市科技創新計劃重點項目，靶向轉錄因子STAT3 特異性抗腫瘤候選藥物研發 2021年1月-2023年12月，100萬參與人
  14. 吉林省科技發展-重點研發項目，一種新型靶向腫瘤免疫關鍵調控通路抑制劑的開發及臨床前評價研究，2020年1月-2023年12月，子課題負責人
  15. 吉林省科技發展-重點研發項目，抗腫瘤候選藥物的成藥性評價及臨床前研究，2020年1月-2023年12月，子課題負責人
  16. 廣東省研究生教育創新計劃-示範課程建設，2022SFKC005，項目負責人

 

學術論文(Publications)&發明專利(Patents)

 

2019年至今,國家發明專利及PCT專利 (Patents)

  1. 國家發明專利申請：一種苯并吡啶類化合物及其制備方法與應用，202311149238.6

  2. 國家發明專利授權：一種喹啉類SNX3抑制劑在制備抗心力衰竭組合物中的應用，專利号：ZL 202310141309.1 

  3. 國家發明專利授權：一種腎清除型雙通道光學納米探針及其制備方法和應用，專利号：ZL 202211596211.7 

  4. 國際PCT優先權：Use of Boric Acid Small Molecule Compound in Preparation of Drugs for Enhancing Curative Effect of Immune Checkpoint Inhibitor and Treating Leukemia，WO 2023245847A1

  5. 國家發明專利授權：一種苯并咪唑并吡嗪-3-甲酰胺化合物及其制備方法與應用，專利号： ZL 2022109687659 

  6. 國際PCT優先權：1-Aminobenzo[4,5]Midazo[1,2-a]Pyrazine-3-Formamide Compound, and Preparation Therefor and Use Thereof，WO2023130701

  7. 國際PCT優先權：Benzoimidazo Pyrazine-3-Carboxamide Compound Targeting A2A and Anti-tumor Immunological Funcation Thereof, WO 2023165165A1 

  8. 國家發明專利授權：一種硼酸類小分子化合物在制備增強免疫檢查點抑制劑療效及治療白血病藥物中的應用，專利号：ZL 202210713434.0

  9. 國際PCT優先權：Boric Acid Compound, Preparation Method and Use Thereof，WO2023168851A1

  10. 國家發明專利授權：一類反義寡核苷酸分子及其在制備治療惡性腫瘤藥物中的應用，ZL 202210611813.9

  11. 國家發明專利授權：嘧啶并吡咯類KRAS抑制劑及其制備方法與應用，專利号：ZL 202210578996.9

  12. 國際PCT優先權：A series of the oligonucleotide RNA molecules and their applications in anti-cancer drug development，WO 2023029489A1

  13. 國際PCT優先權：A derivative of nitrofuran molecule and acts as a ferroptosis inducer and applications in overcoming chemoresistance of gastric cancer, WO 2022218362A1

  14. 國家發明專利授權：靶向A2A的苯并咪唑并吡嗪-3-甲酰胺及其腫瘤免疫功能，專利号：ZL 202210200549.X 

  15. 國家發明專利授權：1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺類化合物及其制備和應用，專利号：ZL 202210018141.0

  16. 國家發明專利授權：一種硼酸化合物制備方法及用途，專利号：ZL 2022102289627

  17. 國家發明專利授權：一種寡核苷酸RNA雙鍊分子及其在制備治療惡性腫瘤藥物中的應用，ZL 202111034572.8

  18. 國家發明專利授權：含環丙烷結構的聯苯類衍生物及其制備方法和應用，專利号：ZL  202111364348.5

  19. 國家發明專利授權：硝基呋喃類化合物、藥物組合物及其制備方法和用途，ZL 202110407970.3 

  20. 國際PCT優先權：Imidazo Pyridine Compound, Pharmaceutical Composition Containing the Compound, Preparation Method Therefor, and Use Thereof，WO 2021088265A1 

  21. 國家發明專利授權：一種硝基呋喃類小芬化合物在制備誘導鐵死亡和/或減緩胃癌化療耐藥藥物中的應用 專利号：ZL 202110407948.9 

  22. 國家發明專利授權：一種3-芳基香豆素類衍生物及其制備方法和用途，專利号：ZL 202110223478.0

  23. 國家發明專利授權：一種取代吡啶并咪唑類化合物及其在制備治療惡性腫瘤疾病藥物中的應用，專利号：ZL 202010245491.1

  24. 國家發明專利授權：一種四氫咪唑[1,2-a]吡嗪類化合物、組合物及其制備方法與應用，專利号：ZL 202011327191.4 

  25. 國家發明專利授權：一種小分子STAT3抑制劑WZ-2-033及其在制備治療乳腺癌和胃癌中的應用，專利号：ZL 202010629937.0 

  26. 國家發明專利授權：一種吡啶并咪唑類STAT3抑制劑在制備延緩或逆轉TKI獲得性耐藥藥物中的應用，專利号：ZL 202010257389.3 

  27. 國家發明專利授權：咪唑并吡啶類化合物、包含該化合物的藥物組合物及其制備方法和用途, 專利号：ZL 201911070864.X

  28. 國家發明專利授權：一種喹啉類STAT3特異性抑制劑及其制備方法和應用, 專利号：ZL 201910300532.X 

  29. 國家發明專利授權：一種四氫異喹啉類衍生物及其合成方法和應用, 專利号：ZL 201911082947.0 

  30. 國家發明專利授權：一種含芳醚取代惡唑烷酮羧酸酯類衍生物及其制備方法和應用，專利号：ZL 201910065130.6

 

2018年至今, 學術論文 (Selected Publications)

  1. Ziyou Lin, Jingwei Li, Jian Zhang, Weineng Feng, Jiaye Lu, Xiaofan Ma, Wen Ding, Shumin Ouyang, Jinjian Lu, Peibin Yue, Guohui Wan, Peiqing Liu, Xiaolei Zhang*. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR-TKIs in non-small lung cancer. Cancer Research. 2023 Jul 5;83(13):2187-2207. (中科院一區， IF=13.31 )

  2. Jianshan Mo, Lin Deng, Keren Peng, Shumin Ouyang, Wen Ding, Linlin Lou, Ziyou Lin, Jianzheng Zhu, Jingwei Li, Qiyi Zhang, Pengyan Wang, Yuanzhen Wen, Xiaobing Chen, Peibin Yue, JinJian Lu, Kai Zhu, Yongjiang Zheng*, Yuanxiang Wang*, Xiaolei Zhang *. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia. Journal of Hematology & Oncology. 2023 Feb 27;16(1):15. (中科院一區，IF=25.56)

  3. Jiaye Lu, Jingwei Li, Ziyou Lin, Huaxuan Li, Linlin Lou, Wen Ding, Shumin Ouyang, Wu Yonghui, Yuanzhen Wen, Xiaobing Chen, Peibin Yue, Yuanxiang Wang, Jinjian Lu, Peiqing Liu, Jinjian Lu*,Jian Zhang*, Weineng Feng*, Xiaolei Zhang*. Reprogramming of TAMs by STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Letters. 2023 May 4;564:216205.  (中科院一區，IF=9.67)

  4. Tongfei Jin, Zhijing Zhang, Zhenghui Kang, Jianshan Mo, Xiaotong Yue, Ziyou Lin, Xiang Fu, Chang Liu, Hang Ma, Xiaolei Zhang*, Wenhao Hu*.Discovery and Optimization of Novel Biphenyl Derivatives BearingCyclopropyl Linkage as Potent Programmed Cell Death-1/ProgrammedCell Death-Ligand 1 Inhibitors. J Med Chem. 2023 May 25;66(10):6811-6835.. (中科院一區，IF=8.04 )

  5. Shumin Ouyang, Huaxuan Li, Linlin Lou, Qiuyao Huang, Zhenhua Zhang, Jianshan Mo, Min Li, Jiaye Lu, Kai Zhu, Yunjie Chu, Wen Ding, Jianzheng Zhu, Ziyou Lin, Lin Zhong, Junjian Wang, Peibin Yue, James Turkson, Peiqing Liu*, Yuanxiang Wang*, Xiaolei Zhang*. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biology. 2022, (52) 102317 (中科院一區， IF=10.79 )

  6. Yang Ge, Jun-Jie Deng, Jianzheng Zhu, Lu Liu, Shumin Ouyang, Zhendong Song, Xiaolei Zhang*, Xiao-Feng Xiong*, Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma, Acta Pharmaceutica Sinica B, 2022, Aug;12(8):3326-3340 (中科院一區，IF=14.90 )

  7. Qiyi Zhang, Wen Ding, Jianshan Mo, Shumin Ouyang, Ziyou Lin, Keren Peng, Guopin Liu, Jinjian Lu, Peibin Yue, Jinping Lei, Yandong Wang*, Xiaolei Zhang*. Novel STAT3 Oligonucletide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma. Acta Pharmacol Sin. 2024 Aug;45(8):1701-1714 (中科院一區， IF=7.19)

  8. Lin Deng, Jianshan Mo, Yi Zhang, Keren Peng, Huaxuan Li, Shumin Ouyang, Zongbo Feng, Wei Fang, Jianwei Wei, Deqin Rong, Xiaolei Zhang*, Yuanxiang Wang*. Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3.  J Med Chem. 2022 Oct 13;65(19):13094-13111(中科院一區，IF=8.04 )

  9. Shuhao Liu, Shuhao Liu, Wen Ding, Weifeng Huang, Zhijing Zhang, Yinfeng Guo, Qiyi Zhang, Linna Wu, Yukai Li, Rui Qin, Jiahao Li, Taoda Shi*, Xiaolei Zhang*, Jinping Lei*, and Wenhao Hu*. Discovery of Novel Benzo[4,5]imidazo[1,2-a]pyrazin-1-amine-3-amide-one Derivatives as Anticancer Human A2A Adenosine Receptor Antagonists. J. Med. Chem. 2022, Jul 14;65(13):8933-8947 (中科院一區，IF=8.04 )

  10. Huaxuan Li , Shumin Ouyang , Yi Zhang , Keren Peng , Wei Fang, Zhiqing Liu, Chang-Yun Wang , Xiaolei Zhang*, Yuanxiang Wang*. Structural optimization of Imidazo[1, 2-a]pyridine derivatives for the treatment of gastric cancer via STAT3 signaling pathway. Eur J Med Chem. 2022, 244,114858  (中科院一區， IF=7.09 )

  11. Zhendong Song, Linlin Lou, Guangjin Fan, Lu Liu, Yang Ge, He Liu, Albert S.C. Chan, Xiaolei Zhang*, Xiaofeng Xiong*. Identification of Novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C  Inhibitors with Anticancer Effects. Eur J Med Chem. 2022, Nov 9th, doi.org/10.1016/ j.ejmech.2022.114907  (中科院一區， IF=7.09 )

  12. Shumin Ouyang, Qiyi Zhang, Linlin Lou, Kai Zhu, Zeyu Li, Peiqin Liu*, Xiaolei Zhang*. The double-edged sword of SIRT3 in cancer and its therapeutic applications. Frontiers in Pharmacology, 2022, April 27th, (13):871560 ( 中科院二區，IF=5.99 )

  13. Huanxin Xue, Jiaye Lu, Hongwei Yan, Ju Huang, Hai-Bin Luo, Man Shing Wong, Yuqi Gao*, Xiaolei Zhang*, Lei Guo*. γ-Glutamyl transpeptidase–activated indole-quinolinium based cyanine as a fluorescence turn-on nucleolus-targeting probe for cancer cell detection and inhibition. Talanta，2022 Jan 15;237:122898 (中科院二區， IF=6.56 )

  14. Guangjin Fan, Linlin Lou, Zhendong Song*, Xiaolei Zhang*, Xiao-Feng Xiong*. Targeting mutated GTPase KRAS in tumor therapies. Eur J Med Chem. 2021; 226:113816  (中科院一區， IF=7.09 )

  15. Yan Zhong, Lin Deng, Shuo Shi, Qiu-yao Huang, Shu-min Ou-Yang, Jian-shan Mo, Kai Zhu, Xin-ming Qu, Pei-qing Liu*, Yuan-xiang Wang* and Xiao-lei Zhang*.The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharmacol Sin. 2022 Apr;43(4):1013-1023 (中科院一區， IF=7.19)

  16. Qiuyao Huang, Yan Zhong, Bingbing Li, Shumin Ouyang, Lin Deng, Jianshan Mo, Shuo Shi, Nan Lv, Ruibo Wu, Peiqing Liu, Wenhao Hu, Xiaolei Zhang* Yuanxiang Wang*. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). Eur J Med Chem. 2021;221:113525. (中科院一區， IF=7.09 )

  17. Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P*, Wang Y*, Zhang X*. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021; 11(2):824-840. (中科院一區， IF=11.60 )

  18. Yang Ge, Shuo Shi, Jun-Jie Deng, Xue-Ping Chen, Zhendong Song, Lu Liu, Linlin Lou, Xiaolei Zhang*, Xiao-Feng Xiong*.Design, Synthesis, and Evaluation of Small Molecule Gαq/11 Protein Inhibitors for the Treatment of Uveal Melanoma. J Med Chem. 2021,64(6):3131-3152. (中科院一區， IF=8.04 )

  19. Xiao-lei Zhang#, Zhuo-ming Li#, Jian-tao Ye, Jing Lu, Lingyu Linda Ye, Chun-xiang Zhang, Pei-qing Liu* and Dayue D Duan*. Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta Pharmacol Sin. 2020 Nov; 41(11): 1377–1386. (中科院一區， IF=7.19 )

  20. Qiuyao Huang, Yan Zhong, Hui Dong, Qiyao Zheng, Shuo Shi, Kai Zhu, Xinming, Wenhao Hu, Xiaolei Zhang*, Yuanxiang Wang*. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? Eur J Med Chem. 2020 ;187: 111922.  (中科院一區， IF=7.09 )

  21. Jingyan Li , Junying Huang,  Jing Lu, Zhen Guo, Zhuoming Li, Hui Gao, Panxia Wang, Wenwei Luo, Sidong Cai, Yuehuai Hu, Kaiteng Guo, Luping Wang, Zhenzhen Li, Minghui Wang, Xiaolei Zhang*, Peiqing Liu*. Sirtuin 1 represses PKC-ζ activity through regulating interplay of acetylation and phosphorylation in cardiac hypertrophy, British Journal of Pharmacology, 2019, 176(3):416-435  (中科院藥學一區， IF=9.47 )

  22. Lei Sun, Ruonian Liu, Zong-Jian Wu, Zheng-Yu Liu, Arabella H Wan, Shijia Yan, Chuwei Liu, Heng Liang, Min Xiao, Nan You, Yawen Lou, Yuan Deng, Xianzhang Bu, Dongshi Chen, Jun Huang, Xiaolei Zhang, Dong-Ming Kuang, Guohui Wan*. Gastroenterology . 2024 Mar;166(3):466-4824. (中科院一區， IF=16.60 )

  23. 張芷菁, 張啟怡, 金祖翼, 朱凱, 丁文*, 張小雷*. 靶向腺苷A2A受體的腫瘤免疫治療研究進展(Progress for targeting adenosine A2A receptors in cancer immunotherapy), 藥學學報 Acta Pharmaceutica Sinica, 2022, 57(9):2557−2569

  24. Ziyou Lin; Arabella H Wan; Lei Sun; Heng Liang; Yi Niu; Yuan Deng; Shijia Yan; Qiao-Ping Wang; Xianzhang Bu; Xiaolei Zhang; Kunhua Hu*; Guohui Wan*; Weiling He*. N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis. Molecular Therapy, 2023 Feb 1;31(2):517-534 (中科院一區， IF=12.91 )

  25. Wang B, Wan AH, Xu Y, Zhang RX, Zhao BC, Zhao XY, Shi YC, Zhang X, Xue Y, Luo Y, Deng Y, Neely GG, Wan G*, Wang QP*. Identification of indocyanine green as a STT3B inhibitor against mushroom α-amanitin cytotoxicity. Nat Commun. 2023 May 16;14(1):2241. (中科院一區， IF=16.60 )

  26. Jian Li, Yang Ge, Junxiang Huang, Kristan Stromgaard, Xiaolei Zhang, Xiaofeng Xiong*. Heterotrimeric G Proteins as Therapeutic Targets in Drug Discovery. J Med Chem. 2020 May 28;63(10):5013-5030 (中科院一區，IF=8.04 )

  27. Wenjing Yu, Yuehuai Hu, Zhiping Liu, Kaiteng Guo, Dinghu Ma, Mingxia Peng, Yuemei Wang , Jing Zhang, Xiaolei Zhang, Panxia Wang, Jiguo Zhang, Peiqing Liu*, Jing Lu*. Sorting nexin 3 exacerbates doxorubicin-induced cardiomyopathy via regulation of TFRC-dependent ferroptosis. Acta Pharm Sin B. 2023 Dec;13(12):4875-4892. (中科院一區，IF=14.90 )

  28. 石碩、朱凱、熊曉峰*、張小雷*。Gq 突變在葡萄膜黑色素瘤中的作用及其抑制劑研究進展 （Study of Gq mutations and their inhibitors in uveal melanoma）。藥學學報 Acta Pharmaceutica Sinica 2020, 55(7): 1382 −1392

  29. Mu-Yang Huang, Yu-Chi Chen, Wen-Yu Lyu, Xin-Yu He, Zi-Han Ye, Can-Yu Huang, Xin-Ling He, Xiuping Chen, Xiaobing Chen, Baoxian Zhang, Guoyin Kai, Xiaolei Zhang, Ting Li, Mingqing Huang, Jin-Jian Lu*. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacol Res. 2023 Dec:198:106988. doi: 10.1016/j.phrs.2023.106988  ( 中科院藥學一區，IF=9.30 )

  30. Chun-Cao Xu, Yi-Fan Lin, Mu-Yang Huang, Xiao-Lei Zhang, Pei Wang, Ming-Qing Huang, Jin-Jian Lu*. Paraptosis: a non-classical paradigm of cell death for cancer therapy. Acta Pharmacol Sin. 2024 Feb;45(2):223-237.(中科院一區， IF=7.19 )

  31. Jing Lu, Suowen Xu, Yuqing Huo, Duanping Sun, Yuehuai Hu, Junjian Wang, Xiaolei Zhang, Panxia Wang, Zhuoming Li, Mengya Liang, Zhongkai Wu*, Peiqing Liu*. Sorting nexin 3 induces heart failure via promoting retromer-dependent nuclear trafficking of STAT3. Cell death and differentiation. 2021 Oct;28(10):2871-2887  (中科院一區， IF=15.83 )

  32. Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xaiolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu*, Fanghai Han*, Junjian Wang*. 2020 Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin, Acta Pharmaceutica Sinica B, 2020,10(12), 2313-2322  (中科院一區， IF=14.90 )

  33. Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W*, Wan G*. RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. The EMBO Journal. 2020 Jun 17;39(12):e103181.  (中科院一區， IF=14.01 )

  34. Yuting Zhang, Weiting Lu, Xiaolei Zhang, Jing Lu, Suowen Xu, Shaorui Chen, Zhi Zhong, Ting Zhou, Quan Wang, Jianwen Chen*, Peiqing Liu*. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacol Res. 2019 Sep;147:104307  ( 中科院藥學一區，IF=9.30 )

  35. Michelle B. Trevino#, Xiaolei Zhang#, Robert A. Standley, Miao Wang,Xianlin Han, Felipe C. G. Reis, Muthu Periasamy, Gongxin Yu, Daniel P. Kelly, Bret H. Goodpaster,Rick B. Vega,1,2 and Paul M. Coen*.Loss of mitochondrial energetics is associated with poor recovery of muscle function but not mass following disuse atrophy. Am J Physiol Endocrinol Metab. 2019 Nov 1; 317(5): E899–E910.

  36. Xiaolei Zhang, Trevino MB, Wang M, Gardell SJ, Ayala JE, Han X, Kelly DP, Goodpaster BH, Vega RB, Coen PM. Impaired Mitochondrial Energetics Characterize Poor Early Recovery of Muscle Mass Following Hind Limb Unloading in Old Mice, J Gerontol A Biol Sci Med Sci. 2018,73(10):1313-1322 (中科院一區， IF=6.59)

  37. Stephen J Gardell, Xiaolei Zhang, Nidhi Kapoor, Christopher Petucci, Paul M Coen. Metabolomics Analyses of Muscle Atrophy Induced by Hind Limb Unloading. Methods Mol Biol. 2019;1996:297-309

  38. Giovanna Distefano, Robert A. Standley, Xiaolei Zhang, Elvis A. Carnero, Fanchao Yi, Heather H. Cornnell, Paul M. Coen*. Physical activity unveils the relationship between mitochondrial energetics, muscle quality, and physical function in older adults. J Cachexia Sarcopenia Muscle. 2018 Apr; 9(2): 279–294. (中科院一區， IF=12.06 )

專著 （Book Chapter）

 

Stephen J. Gardell, Xiaolei Zhang, Nidhi Kapoor, Christopher Petucci, and Paul M. Coen. Metabolomics: Methods and Protocols, Springer，2019, 297-310

 

Hui Zhou, Yinqiu Cui, Haijing Wang, Yue Xu, Xiaolei Zhang.  An Introduction to Molecular Archaeology. 科學出版社(Science Press)  in 2008 Chapter 9 and 10 (Chapter 9: Dating mining and biostatistics analysis of ancient DNA information, Chapter 10: The application of bioinformatics and statistics tools in ancient DNA research)

 

 

2018年之前，學術論文 （Selected Publications）

 

1. Xiaolei Zhang, Peibin Yue , Brent D.G. Page , Tianshu Li , Wei Zhao , Andrew T. Namanja , David Paladino , Jihe Zhao , Yuan Chen , Patrick T. Gunning , James Turkson . Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. USA (PNAS) 2012, 109 (24): 9623-9628 (中科院一區， IF=12.78)

 

2. Zhang X, Blaskovich MA, Forinash KD, Sebti SM.  Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. British Journal of Cancer. 2014,111(5):894-902 (中科院一區， IF=9.07 )

 

3.Xiaolei Zhang, Ying Sun, Roberta Pireddu, Hua Yang, Murali K. Urlam , Harshani Lawrence , Wayne C. Guida , Nicholas J. Lawrence, Said M Sebti. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Research 2013, 73(6):1922-1933  (中科院一區， IF=13.31 )

 

4. Teng P#, Zhang X#, Wu H, Qiao Q, Sebti SM, Cai J. Identification of novel inhibitors that disrupt STAT3-DNA interaction from a γ-AApeptide OBOC combinatorial library. Chem Commun (Camb). 2014 Aug 14;50(63):8739-42. (#Co-first Author)  ( IF=6.22 )

 

5. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010, 79(10):1398-409. ( IF=6.10)

 

6. Peibin Yue, Xiaolei Zhang, David Paladion, James Turkson. Hyperactive EGF receptor and Stat3 signaling promote enhanced colony-forming ability motility and migration of Cisplatin-resistant ovarian cancer cells. Oncogene 2012, 31(18):2309-22 (中科院一區， IF=8.76 )

 

7. Astha Malhotra, Xiaolei Zhang, James Turkson, Swadeshmukul Santra. Buffer-Stable Chitosan–Polyglutamic Acid Hybrid Nanoparticles for Biomedical Applications.Macromolecular Bioscience 2013 May;13(5):603-13 ( IF=5.86)

 

8. Awet Tecleab, Xiaolei Zhang and Said M. Sebti Ral GTPase down regulation stabilizes and reactivates p53 to inhibit malignant transformation. Journal of Biological Chemistry 2014 Nov 7;289(45):31296-309 ( IF=5.49)

 

9. Mitra, Rajendra; Doshi, Mona; Zhang, Xiaolei; Tyus, Jessica; Bengtsson, Niclas; Fletcher, Steven; Page, Brent; Turkson, James; Gesquiere, Andre; Gunning, Patrick; Walter, Glenn; Santra, Swadeshmukul. An activatable multimodal/multifunctional nanoprobe for direct imaging of intercellular drug delivery.  Biomaterials. 2012, 33(5):1500-8 (中科院一區， IF=15.30 )

 

10. Fletcher S, Singh J, Zhang X, Yue P, Page BD, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J, Gunning PT. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem. 2009, 10(12):1959-64 ( IF=3.46 )

 

11. Fletcher S, Page BD, Zhang X, Yue P, Li ZH, Sharmeen S, Singh J, Zhao W, Schimmer AD, Trudel S, Turkson J, Gunning PT. Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules. ChemMedChem. 2011 6(8):1459-70 ( IF=3.54 )

 

12. Drewry JA, Fletcher S, Yue P, Marushchak D, Zhao W, Sharmeen S, Zhang X, Schimmer AD, Gradinaru C, Turkson J, Gunning PT. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun (Camb). 2010 ,;46(6):892-4 ( IF=6.22 )

 

13. Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett. 2011, 21(18):5605-9 ( IF=2.82 )

 

14. Vijay M. Shahani, Peibin Yue, Sina Haftchenary, Wei Zhao, Julie L. Lukkarila, Xiaolei Zhang, Daniel Ball, Christina Nona, Patrick T. Gunning, and James Turkson. Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies  ACS Med. Chem. Lett., 2011 ,2(1):79-84. ( IF=4.63 )

 

15.  Shahani VM, Yue P, Fletcher S, Sharmeen S, Sukhai MA, Luu DP, Zhang X, Sun H, Zhao W, Schimmer AD, Turkson J, Gunning PT. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem. 2011, 19(5):1823-38 ( IF=3.64 )

 

16. Murali K. Urlam, Roberta Pireddu, Yiyu Ge, Xiaolei Zhang, Ying Sun,Harshani R. Lawrence, Wayne C. Guida,Saïd M. Sebti,Nicholas J. Lawrence. Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors. Medical Chemistry Communications 2013 Jun;4(6):932-941

 

17. Y. Changchun, X. Li, Z. Xiaolei, Z. Hui, Z. Hong. Genetic analysis on Tuoba Xianbei remains excavated from Qilang mountain cemetery in Qahar Right Wing Middle Banner of Inner Mongolia. FEBS Letters, 2006, 580(26): 6242–6246

 

18. Lu Han, Dawei Cai, Huixin Yu, Xiaolei Zhang, Hui Zhou, Hong Zhu. Mitochondria DNA analysis of ancient sheep from Inner Mongolia in the warring state period. Progress in Natural Sciences (China) 2009, 19(10):1049-1055

 

19. Da-Wei Cai, Lu Han, Xiao-Lei Zhang, Hui Zhou . DNA analysis of archaeological sheep remains from China . Journal of Archaeological Sciences, 2007, 34(9):1347-1355

 

20. YU Chang-Chun, XIE Li, ZHANG Xiao-lei, ZHOU Hui, ZHU Hong. Genetic Analyses on the Affinities between Tuoba Xianbei and Xiongnu Population. HEREDITAS (Beijing), 2007,29(10):1223-1229

 

21. YU Chang-chun, LI Wen-rong, XIE Li, ZHANG Xiao-lei, ZHOU Hui, ZHU Hong. Genetic Analysis on Mitochondrial DNA of Xibe Population in Xinjiang. Journal of Jilin University (Science Edition), 2007,45(5):485-489

 

22. Yue Xu, Xiaolei Zhang, Yinqiu Cui, Quanchao Zhang, Hui Zhou, Hong Zhu. Genetic Structure Analysis of Human Remains from Khitan Noble Necropolis. Chem. Res. Chinese U. 2006, 22(2):123-128

 

23. Fu Yuqin, Xu Xuelian, Zhang Xiaolei, Zhouhui, Zhu Hong. Phylogenetic analysis of mtDNA from the ancient Human of Yuan Dynasty in Inner-Mongolia in China . Chem. Res. Chinese U. 2006, 22(2):177 -180

 

24.  WANG Haijing, LIU Weiqiang, FU Yuqin, ZHANG Xiaolei, et al. Molecular biological analysis of remains from Jiangjungou cemetery in Inner Mongolia . Progress in Natural Science. 2006, 16(7): 894-898

 

25.  Yu Chang-chun, Xie Li, Zhang Xiao-lei, Zhou Hui, Zhu Hong. Analyses on the genetic affinities between Tuoba Xianbei and minorities from northern China . Journal of Northerneast Normal University (Natural Science Edition), 2007, 39(4):121-126

 

26.  Zhang Xiao-lei，Cui Yin-qiu, Lv Hui-ying, Zhou Hui. Application of Phylogenetic Analysis in Ancient DNA Research. Journal of Jilin University (Science Edition), 2005, 43(5):696-701

 

27.  Xu Yue, Zhang Xiao-lei, Zhang Quan-chao, Cui Yin-qiu, Zhou Hui. Mitochondrial DNA Analysis of Turki Human Remain. Journal of Jilin University (Medicine Edition), 2006, 32(2): 248 - 250

 

28.  Xu Yue, Zhang Xiao-lei, Zhang Quan-chao, etal. Genetic Analysis between Ancient Khitan Population and Modern Daur Population. Journal of Jilin University (Science Edition), 2006, 44(6):997-1000